Catalyst Pharmaceuticals Stock Revenue
| CPRX Stock | USD 21.12 0.03 0.14% |
Catalyst Pharmaceuticals fundamentals help investors to digest information that contributes to Catalyst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Catalyst Stock. The fundamental analysis module provides a way to measure Catalyst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Catalyst Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 398.2 M | 418.1 M |
Catalyst | Revenue |
Catalyst Pharmaceuticals Company Revenue Analysis
Catalyst Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Catalyst Pharmaceuticals Revenue | 398.2 M |
Most of Catalyst Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalyst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Catalyst
Projected quarterly revenue analysis of Catalyst Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Catalyst Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Catalyst Pharmaceuticals' stock price.
Catalyst Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Catalyst Pharmaceuticals is extremely important. It helps to project a fair market value of Catalyst Stock properly, considering its historical fundamentals such as Revenue. Since Catalyst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Catalyst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Catalyst Pharmaceuticals' interrelated accounts and indicators.
| -0.86 | -0.86 | -0.56 | -0.86 | -0.51 | ||
| -0.86 | 0.97 | 0.56 | 1.0 | 0.73 | ||
| -0.86 | 0.97 | 0.68 | 0.96 | 0.61 | ||
| -0.56 | 0.56 | 0.68 | 0.55 | -0.1 | ||
| -0.86 | 1.0 | 0.96 | 0.55 | 0.74 | ||
| -0.51 | 0.73 | 0.61 | -0.1 | 0.74 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Catalyst Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Catalyst Pharmaceuticals reported 398.2 M of revenue. This is 94.78% lower than that of the Biotechnology sector and 46.4% lower than that of the Health Care industry. The revenue for all United States stocks is 95.78% higher than that of the company.
Catalyst Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Catalyst Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics of similar companies.Catalyst Pharmaceuticals is currently under evaluation in revenue category among its peers.
Catalyst Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Catalyst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Catalyst Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Catalyst Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Catalyst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Catalyst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Catalyst Pharmaceuticals' value.| Shares | Royce & Associates, Lp | 2024-09-30 | 2 M | Boston Partners Global Investors, Inc | 2024-06-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1.3 M | Kennedy Capital Management Inc | 2024-06-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 18.7 M | Deerfield Management Co | 2024-06-30 | 9.1 M |
Catalyst Fundamentals
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 2.08 B | ||||
| Shares Outstanding | 119.27 M | ||||
| Shares Owned By Insiders | 5.98 % | ||||
| Shares Owned By Institutions | 81.71 % | ||||
| Number Of Shares Shorted | 6.01 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 5.48 X | ||||
| Revenue | 398.2 M | ||||
| Gross Profit | 160.02 M | ||||
| EBITDA | 86.81 M | ||||
| Net Income | 71.41 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 3.56 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 5.54 X | ||||
| Cash Flow From Operations | 143.6 M | ||||
| Short Ratio | 8.20 X | ||||
| Earnings Per Share | 1.18 X | ||||
| Target Price | 32.25 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.76 | ||||
| Market Capitalization | 2.52 B | ||||
| Total Asset | 470.11 M | ||||
| Retained Earnings | 121.27 M | ||||
| Working Capital | 143.27 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
| Net Asset | 470.11 M |
About Catalyst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.